Abstract：For patients with newly diagnosed glioblastoma, tumor treating fields (TTF) combined with temozolomide after radiation therapy is currently one of the standard therapeutic regimens. Recently, TTF has been increasingly applied in combination with radiation therapy since it can delay tumor DNA repair and increase DNA replication stress. The efficacy of TTF has been proven in clinical studies. However, no consensus has been reached regarding the theoretical basis, radiation dose, actual clinical operation, patients' benefit and safety, which remain controversial. In this article, research progress on these topics was reviewed.
Qiao Qiao,Xiao Huiyu,Li Guang. Research progress on tumor treating fields combined with radiation therapy in the treatment of glioblastoma[J]. Chinese Journal of Radiation Oncology, 2023, 32(4): 370-374.
[1] Tan AC, Ashley DM, López GY, et al.Management of glioblastoma: state of the art and future directions[J]. CA Cancer J Clin, 2020,70(4):299-312. DOI: 10.3322/caac.21613. [2] 国家神经系统疾病临床医学研究中心,国家神经系统疾病医疗质量控制中心.中国脑胶质瘤临床管理指南(2020)[M]. 北京:人民卫生出版社,2020. China National Clinical Research Center for Neurological Diseases, National Center for Healthcare Quality Management in Neurological Diseases. Clinical Management Guide for Chinese Brain Glioma[M]. Beijing: People's Medical Publishing House, 2020. [3] 国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版)[J]. 中华神经外科杂志,2019,35(3):217-239. DOI:10.3760/cma.j.issn.1001-2346.2019.03.001. Bureau for Medical Administration of National Health Commission of the People's Republic China. Diagnosis and treatment of brain glioma (2018)[J]. Chin J Neurosurg, 2019,35(3):217-239. DOI:10.3760/cma.j.issn.1001-2346.2019.03.001. [4] Nabors LB, Portnow J, Ahluwalia M, et al.Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020,18(11):1537-1570. DOI: 10.6004/jnccn.2020.0052. [5] 中国抗癌协会脑胶质瘤专业委员会, 胶质母细胞瘤的肿瘤电场治疗专家共识撰写组. 胶质母细胞瘤的肿瘤电场治疗专家共识[J]. 中华神经外科杂志, 2021,37(11):1081-1089.DOI: 10.3760/cma.j.cn112050-20210406-00165. China Cancer Cancer Association Team of Brain Glioma, The Tumor Field Treatment Expert Consensus Writing Group of Glioblastoma. The tumor field treatment expert consensus of glioblastoma[J]. J Chin Neurosurg, 2021,37(11):1081-1089.DOI: 10.3760/cma.j.cn112050-2021 0406-00165. [6] Hong PJ, Kudulaiti N, Wu S, et al.Tumor treating fields: a comprehensive overview of the underlying molecular mechanism[J]. Expert Rev Mol Diagn, 2022,22(1):19-28. DOI: 10.1080/14737159.2022.2017283. [7] Berkelmann L, Bader A, Meshksar S, et al.Tumour- treating fields (TTFields): investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis[J]. Sci Rep, 2019,9(1):7362. DOI: 10.1038/s41598-019-43621-9. [8] Arvind R, Chandana SR, Borad MJ, et al.Tumor-treating fields: a fourth modality in cancer treatment, new practice updates[J]. Crit Rev Oncol Hematol, 2021,168:103535. DOI: 10.1016/j.critrevonc.2021.103535. [9] Mun EJ, Babiker HM, Weinberg U, et al.Tumor-treating fields: a fourth modality in cancer treatment[J]. Clin Cancer Res, 2018,24(2):266-275. DOI: 10.1158/1078- 0432.CCR-17-1117. [10] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005,352(10):987-996. DOI: 10.1056/NEJMoa043330. [11] Stupp R, Taillibert S, Kanner A, et al.Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial[J]. JAMA, 2017,318(23):2306-2316. DOI: 10.1001/jama.2017. 18718. [12] Omar AI.Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma[J]. J Vis Exp, 2014,(92):e51638. DOI: 10. 3791/51638. [13] Mikic N, Poulsen FR, Kristoffersen KB, et al.Study protocol for optimal TTF-2: enhancing tumor treating fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial[J]. BMC Cancer, 2021,21(1):1010. DOI: 10.1186/s12885-021-08709-4. [14] Lu G, Rao M, Zhu P, et al.Triple-drug therapy with bevacizumab, irinotecan, and temozolomide plus tumor treating fields for recurrent glioblastoma: a retrospective study[J]. Front Neurol, 2019,10:42. DOI: 10.3389/fneur. 2019.00042. [15] Bokstein F, Blumenthal D, Limon D, et al.Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study[J]. Front Oncol, 2020,10:411. DOI: 10.3389/fonc.2020.00411. [16] Song A, Bar-Ad V, Martinez N, et al.Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma[J]. J Neurooncol, 2020,147(3):653-661. DOI: 10.1007/s11060-020-03466-z. [17] Miller R, Song A, Ali A, et al.Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma[J]. Front Oncol, 2022,12:896246. DOI: 10.3389/fonc. 2022.896246. [18] Nour Y, Pöttgen C, Kebir S, et al.Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I/II trial[J]. J Appl Clin Med Phys, 2021,22(1):242-250. DOI: 10.1002/acm2.13144. [19] Kirson ED, Dbalý V, Tovarys F, et al.Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors[J]. Proc Natl Acad Sci U S A, 2007,104(24):10152-10157. DOI: 10.1073/pnas.07029 16104. [20] Shteingauz A, Porat Y, Voloshin T, et al.AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)[J]. Cell Death Dis, 2018,9(11):1074. DOI: 10.1038/s41419-018- 1085-9. [21] Shi P, Tian J, Ulm BS, et al.Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity[J]. Front Oncol, 2022,12:837589. DOI: 10.3389/fonc.2022.837589. [22] Neuhaus E, Zirjacks L, Ganser K, et al. Alternating Electric Fields (TTFields) Activate Ca(v)1.2 Channels in Human Glioblastoma Cells[J]. Cancers (Basel), 2019,11(1)DOI: 10.3390/cancers11010110. [23] Chen D, Le SB, Hutchinson TE, et al. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma[J]. J Clin Invest, 2022,132(8)DOI: 10.1172/JCI149258. [24] Guo X, Yang X, Wu J, et al. Tumor-Treating Fields in Glioblastomas: Past, Present,Future[J]. Cancers (Basel), 2022,14(15)DOI: 10.3390/cancers14153669. [25] Giladi M, Munster M, Schneiderman RS, et al.Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells[J]. Radiat Oncol, 2017,12(1):206. DOI: 10.1186/s13014-017-0941-6. [26] Karanam NK, Ding L, Aroumougame A, et al.Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy[J]. Transl Res, 2020,217:33-46. DOI: 10.1016/j.trsl.2019.10.003. [27] Chang E, Pohling C, Beygui N, et al.Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields[J]. J Neurooncol, 2017,134(2):259-268. DOI: 10.1007/s11060-017-2534-5. [28] Toms SA, Kim CY, Nicholas G, et al.Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial[J]. J Neurooncol, 2019,141(2):467-473. DOI: 10.1007/s11060-018-03057-z. [29] Vymazal J, Wong ET. Response patterns of recurrent glioblastomas treated with tumor-treating fields[J]. Semin Oncol, 2014,41 Suppl 6:S14-24. DOI: 10.1053/j.seminoncol.2014.09.009. [30] 韩磊, 汪洋, 倪春霞, 等. 运用Compass系统验证肿瘤治疗电场(TTF)对胶质母细胞瘤放疗剂量的影响[J].中国医疗器械信息,2021,27(9):34-36. DOI:10.15971/j.cnki.cmdi.2021.09.013. Han L, Wang Y, Ni CX, et al.Effects of tumor treating fields (TTF) arrays on radiation dose of glioblastoma was verified by the Compass[J]. China Medical Device Information, 2021,27(9):34-36. DOI:10.15971/j.cnki.cmdi.2021.09.013. [31] Li T, Shukla G, Peng C, et al.Dosimetric Impact of a Tumor Treating Fields Device for Glioblastoma Patients Undergoing Simultaneous Radiation Therapy[J]. Front Oncol, 2018,8:51. DOI: 10.3389/fonc.2018.00051. [32] Straube C, Oechsner M, Kampfer S, et al.Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study[J]. Radiat Oncol, 2018,13(1):31. DOI: 10.1186/s13014-018-0976-3. [33] Stachelek GC, Grimm J, Moore J, et al.Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy[J]. Adv Radiat Oncol, 2020,5(1):62-69. DOI: 10.1016/j.adro.2019.08.005. [34] Lacouture ME, Anadkat MJ, Ballo MT, et al.Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma[J]. Front Oncol, 2020,10:1045. DOI: 10.3389/fonc.2020. 01045. [35] 中国抗癌协会脑胶质瘤专业委员会. 胶质母细胞瘤肿瘤电场治疗头皮护理专家共识[J]. 中华现代护理杂志, 2022,28(21):2801-2807.DOI: 10.3760/cma.j.cn115682-2021 1206-05508. Brain Glioma Professional Committee of China Anti-Cancer Association. Expert consensus on the scalp care of glia blastoma tumor field therapy[J]. Chin Mod Care J, 2022,28(21):2801-2807.DOI: 10.3760/cma.j.cn115682-20211206-05508.
2023, Vol. 32 
